A federal jury in Cleveland found CVS, Walgreens, and Walmart pharmacies responsible for contributing to the opioid crisis; concerns rise after the death of a woman who received infusions of the Alzheimer disease drug Aduhelm; Juul vowed to stop advertising its vaping products to young people in Arizona.
A federal jury said CVS, Walgreens, and Walmart pharmacies recklessly distributed massive amounts of pain pills in 2 Ohio counties, the Associated Press reported. Lake and Trumbull counties argued the 3 chain pharmacies did not stop distributing the pills after they caused hundreds of overdose deaths and cost each county about $1 billion. Attorneys for the pharmacies said they followed policies when pharmacists had concerns and notified authorities of suspicious orders, emphasizing that doctors controlled how many pills were prescribed, not the pharmacists. This verdict comes weeks after juries in Oklahoma and California found multiple drug companies not liable for their roles in the opioid crises in each state, and it could set the tone for other state juries that want to hold pharmacies accountable. CVS Health, Walgreen Co, and Walmart Inc each said they will appeal the verdict.
Concerns about the safety of Biogen’s Alzheimer disease drug Aduhelm have increased following the death of a 75-year-old woman who died after being infused with the drug, The New York Times reported. The woman lived in Canada and was a participant in a clinical trial for the drug. She died in September, experiencing seizures and brain swelling after receiving infusions of Aduhelm. A doctor reported her death to the FDA’s adverse event reporting system, and the death is being investigated by both the FDA and Biogen. In a statement, Biogen said the cause of death is unknown at this time.
Major e-cigarette company Juul Labs is set to pay the state of Arizona $14.5 million in a consumer fraud lawsuit settlement, vowing to stop marketing to young people in the state, as reported by the Associated Press. The agreement requires Juul not to advertise near schools or on social media, nor target anyone under 21. This is the second settlement Juul has reached with Arizona state prosecutors and ends litigation filed in January 2020 against Juul and Eonsmoke claiming the 2 companies illegally targeted younger people in their marketing. Although Arizona previously won a $22.5 million judgment against Eonsmoke, the state has not collected any of the money. Juul Labs stopped all advertising before the lawsuit and admitted no wrongdoing in settling the case, calling it “another step in our ongoing effort to reset our company.” The company has also stopped selling all flavored products except menthol.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More